User Profile
/
Watchlists
/
Beat the Benchmark 2026 Portfolio - Possible list

Beat the Benchmark 2026 Portfolio - Possible list

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Clive_Thompson

184 followers106 views

Watching

Company	Price & Valuation	My FV & Narrative	Valuation	Growth	Analyst Target
EMR Emerald Resources AU$6.3921.4% undervalued intrinsic discount 25.5%7D 24.8%3M AU$8.13author fair value 19 Junauthor updated this narrative Analysts are bullish with a Price Target of A$8.13 based on 65.4% annual revenue growth forecasts.
AU AngloGold Ashanti US$90.9226.3% undervalued intrinsic discount 15.9%7D 6.1%3M AN US$123.29author fair value 28 Mayauthor updated this narrative AU: Strengthening Margins And Revenue Will Drive Upward Momentum In Coming Years
AGI Alamos Gold CA$52.7336.7% undervalued intrinsic discount 14.7%7D -2.9%3M AN CA$83.26author fair value 05 Junauthor updated this narrative Analysts Lift Alamos Gold Price Target Amid Strong Growth Improved Margins and Positive Outlook
TPC Tutor Perini US$77.8920.5% undervalued intrinsic discount 13.3%7D 7.7%3M AN US$98author fair value 03 Mayauthor updated this narrative Labor Shortages Will Hurt Margins Yet Spark Efficiency Gains
4042 Tosoh JP¥3,019.002.0% overvalued intrinsic discount 8.9%7D 29.4%3M JP¥2.96kauthor fair value 19 Junauthor updated this narrative Analysts are neutral with a Price Target of ¥2,959 based on 7.5% annual revenue growth forecasts.
BS6 Yangzijiang Shipbuilding (Holdings) S$3.6533.2% undervalued intrinsic discount 8.3%7D -9.2%3M KA S$5.46author fair value 04 Junauthor updated this narrative Yangzijiang Shipbuilding Aims for a 30% Profit Margin Boost
MLYS Mineralys Therapeutics US$25.1350.6% undervalued intrinsic discount 5.8%7D 7.9%3M AN US$50.88author fair value 05 Marauthor updated this narrative Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech
RUSTA Rusta SEK 75.5022.6% undervalued intrinsic discount 5.1%7D -17.9%3M AN SEK 97.5author fair value 03 Junauthor updated this narrative Upcoming Store Expansion And Supply Chain Investments Will Increase Future Market Reach
CS AXA €42.538.5% undervalued intrinsic discount 4.9%7D 10.6%3M AN €46.48author fair value 03 Junauthor updated this narrative CS: Rising Profit Margins And Multiples Will Drive Global Expansion
ALHC Alignment Healthcare US$21.4214.1% undervalued intrinsic discount 4.2%7D 18.0%3M AN US$24.92author fair value 30 Mayauthor updated this narrative ALHC: Margin Recovery Will Drive Medicare Advantage Market Share Gains
AGS ageas €67.755.7% overvalued intrinsic discount 4.1%7D 12.3%3M AN €64.11author fair value 12 Decauthor updated this narrative Asian Life Shift And Esure Integration Will Drive Stronger, More Resilient Earnings Ahead
MFC Manulife Financial CA$56.972.9% overvalued intrinsic discount 4.0%7D 22.3%3M AN CA$55.38author fair value 05 Junauthor updated this narrative MFC: Sector Headwinds And Mixed Performance Will Shape Near-Term Outlook
BAER Julius Bär Gruppe CHF 65.905.0% undervalued intrinsic discount 3.4%7D 16.5%3M AN CHF 69.35author fair value 18 Junauthor updated this narrative Digital Transformation And Global Wealth Transfers Will Empower Private Banking
MELI MercadoLibre US$1,631.8228.6% undervalued intrinsic discount 2.7%7D -2.1%3M JO US$2.28kauthor fair value 20 Mayauthor updated this narrative MercadoLibre's 19% Revenue Growth Will Propel Their Future Success
PNFP Pinnacle Financial Partners US$95.5818.2% undervalued intrinsic discount 2.7%7D 15.2%3M AN US$116.79author fair value 05 Junauthor updated this narrative PNFP: Revenue Momentum And Pending Synovus Merger Will Drive Future Upside
966 China Taiping Insurance Holdings HK$21.2615.7% undervalued intrinsic discount 2.6%7D -2.1%3M HK$25.23author fair value 19 Junauthor updated this narrative Analysts are bullish with a Price Target of HK$25.23 based on 103.3% annual revenue growth forecasts.
BDT Bird Construction CA$59.875.5% undervalued intrinsic discount 2.3%7D 72.0%3M AN CA$63.38author fair value 17 Junauthor updated this narrative Sustained Sector Optimism And Major Project Wins Will Support Long-Term Expansion
ARGX argenx €780.2013.7% overvalued intrinsic discount 2.3%7D 31.5%3M KA €686.43author fair value 20 Mayauthor updated this narrative High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug
4206 Aica Kogyo Company JP¥3,533.0012.8% undervalued intrinsic discount 2.1%7D -3.0%3M JP¥4.05kauthor fair value 25 Julauthor updated this narrative Analysts are bullish with a Price Target of ¥4,050 based on 10.5% annual revenue growth forecasts.
LKNC.Y Luckin Coffee US$30.6932.7% undervalued intrinsic discount 1.3%7D -9.7%3M AN US$45.58author fair value 05 Junauthor updated this narrative Chinese Urbanization And Digital Transformation Will Unlock Market Potential
8795 T&D Holdings JP¥4,746.005.3% overvalued intrinsic discount 1.3%7D 27.1%3M AN JP¥4.51kauthor fair value 02 Mayauthor updated this narrative Analysts Lift T&D Holdings Price Target as Revenue Outlook Improves Despite Lower Margins
ADS adidas €173.1012.7% undervalued intrinsic discount 0.6%7D 29.9%3M AN €198.28author fair value 04 Junauthor updated this narrative ADS: Stable Profit Margins Will Support Renewed Confidence Amid Legal Scrutiny
HBAN Huntington Bancshares US$16.8566.7% overvalued intrinsic discount 0.06%7D 11.1%3M MS US$10.11author fair value 27 Sepauthor updated this narrative Overvalued HBAN
999 Xiaocaiyuan International Holding HK$6.8025.1% undervalued intrinsic discount 0%7D -13.5%3M HK$9.08author fair value 19 Decauthor updated this narrative Analysts are bullish with a Price Target of HK$9.08 based on 3.8% annual revenue growth forecasts.
9911 Newborn Town HK$8.1841.4% undervalued intrinsic discount 0%7D -9.9%3M HK$13.97author fair value 25 Julauthor updated this narrative Analysts are bullish with a Price Target of HK$13.97 based on 24.4% annual revenue growth forecasts.
FITB Fifth Third Bancorp US$52.588.4% undervalued intrinsic discount -0.1%7D 20.4%3M AN US$57.42author fair value 06 Junauthor updated this narrative Analyst Commentary Highlights Optimism and Caution on Fifth Third Bancorp Amid Merger and Valuation Shifts
DKSH DKSH Holding CHF 62.6013.7% undervalued intrinsic discount -0.2%7D 9.4%3M AN CHF 72.57author fair value 11 Febauthor updated this narrative Asia Pacific Expansion And Digitalization Will Fuel Sustainable Success
NIC Nicolet Bankshares US$144.5517.0% undervalued intrinsic discount -0.2%7D 2.2%3M US$174.2author fair value 25 Julauthor updated this narrative Analysts are bullish with a Price Target of $174.20 based on 27.0% annual revenue growth forecasts.
EXEL Exelixis US$52.445.6% overvalued intrinsic discount -0.3%7D 27.1%3M AN US$49.65author fair value 11 Junauthor updated this narrative Expanding Global Oncology Markets Will Broaden Patient Access
ONC BeOne Medicines US$262.6836.2% undervalued intrinsic discount -0.4%7D -7.1%3M AN US$411.51author fair value 23 Mayauthor updated this narrative ONC: Pivotal Oncology Trial Data Will Drive Future Upside Momentum
939 China Construction Bank HK$8.7111.1% undervalued intrinsic discount -0.5%7D 7.7%3M AN HK$9.8author fair value 17 Junauthor updated this narrative Mounting Headwinds And Digital Shifts Will Suppress Future Margins
COLB Columbia Banking System US$30.056.3% undervalued intrinsic discount -0.9%7D 13.8%3M AN US$32.08author fair value 06 Junauthor updated this narrative COLB: Upgraded Ratings And Peer-Leading Returns Will Drive Outperformance
SFNC Simmons First National US$21.717.9% undervalued intrinsic discount -1.1%7D 16.1%3M AN US$23.57author fair value 17 Junauthor updated this narrative Urbanization And Digital Adoption Will Transform US Banking
COPN Cosmo CHF 69.7030.3% undervalued intrinsic discount -1.1%7D -11.8%3M KA CHF 100author fair value 16 Mayauthor updated this narrative Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
CCB Coastal Financial US$70.3433.8% undervalued intrinsic discount -1.4%7D -7.6%3M US$106.25author fair value 19 Junauthor updated this narrative Analysts are bullish with a Price Target of $106.25 based on 77.0% annual revenue growth forecasts.
CAMX Camurus SEK 533.0030.8% undervalued intrinsic discount -1.7%7D 16.4%3M AN SEK 770.13author fair value 29 Aprauthor updated this narrative Global Expansion And Regulatory Approvals Will Transform Healthcare Delivery
RNST Renasant US$41.209.6% undervalued intrinsic discount -1.8%7D 18.8%3M AN US$45.57author fair value 15 Junauthor updated this narrative Southeastern Expansion And Merger Synergies Will Create Value
MONY MONY Group UK£1.8235.0% undervalued intrinsic discount -2.1%7D 13.2%3M AN UK£2.8author fair value 04 Junauthor updated this narrative Rising Middle Class And AI Integration Will Expand Markets
RHM Rheinmetall €1,170.2038.1% undervalued intrinsic discount -2.3%7D -24.5%3M AN €1.89kauthor fair value 15 Junauthor updated this narrative Analysts Highlight Cautious Optimism Amid Valuation Gains and Strategic Shifts at Rheinmetall
MRP Millrose Properties US$28.0627.3% undervalued intrinsic discount -2.6%7D -3.4%3M AN US$38.6author fair value 14 Decauthor updated this narrative Long-Term Housing Undersupply And AI Underwriting Will Support Strong Future Performance
MRK Merck US$115.442.6% overvalued intrinsic discount -3.1%7D 1.1%3M BU US$112.55author fair value 28 Sepauthor updated this narrative Merck & Co.: Navigating Pharmaceutical Frontiers Amidst Patent Challenges
EVO Evolution SEK 699.4032.8% undervalued intrinsic discount -3.3%7D 19.4%3M IM SEK 1.04kauthor fair value 04 Junauthor updated this narrative A Monopoly-Quality Business Trading at Distress Multiples — CEO Buying, €346M Buyback Active, 73% Upside to Fair Value
HRMY Harmony Biosciences Holdings US$33.7728.6% undervalued intrinsic discount -4.8%7D 21.4%3M AN US$47.3author fair value 23 Febauthor updated this narrative Expanding Sleep And Rare Disease Markets Will Unlock Future Potential
HACK Hacksaw SEK 73.7026.2% undervalued intrinsic discount -5.0%7D 26.7%3M AN SEK 99.87author fair value 25 Janauthor updated this narrative Expanding Games Portfolio And New Regulated Markets Will Support Long Term Earnings Potential
BETS B Betsson SEK 87.1547.8% undervalued intrinsic discount -5.1%7D -10.4%3M IM SEK 167author fair value 04 Junauthor updated this narrative The Market Is Paying You a 9.3% Dividend and an 18.9% FCF Yield to Wait for a Recovery That's Already Starting
2419 Dekon Food and Agriculture Group HK$45.9654.5% undervalued intrinsic discount -7.6%7D -40.5%3M HK$101.02author fair value 25 Julauthor updated this narrative Analysts are bullish with a Price Target of HK$101.02 based on 10.0% annual revenue growth forecasts.
MNSO MINISO Group Holding US$12.1552.3% undervalued intrinsic discount -7.7%7D -27.6%3M BE US$25.46author fair value 14 Junauthor updated this narrative MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x

Watching

Company	Price & Valuation	My FV & Narrative	Valuation	Growth	Analyst Target
EMR Emerald Resources 25.5%7D 24.8%3M	AU$6.39 21.4% undervalued intrinsic discount	AU$8.13author fair value 19 Junauthor updated this narrative Analysts are bullish with a Price Target of A$8.13 based on 65.4% annual revenue growth forecasts.	PE 41.8x	E 51.6%	AU$8.13
AU AngloGold Ashanti 15.9%7D 6.1%3M	US$90.92 26.3% undervalued intrinsic discount	AN US$123.29author fair value 28 Mayauthor updated this narrative AU: Strengthening Margins And Revenue Will Drive Upward Momentum In Coming Years	PE 13.2x	E 10.6%	US$121.29
AGI Alamos Gold 14.7%7D -2.9%3M	CA$52.73 36.7% undervalued intrinsic discount	AN CA$83.26author fair value 05 Junauthor updated this narrative Analysts Lift Alamos Gold Price Target Amid Strong Growth Improved Margins and Positive Outlook	PE 14.8x	E 17.9%	CA$84.15
TPC Tutor Perini 13.3%7D 7.7%3M	US$77.89 20.5% undervalued intrinsic discount	AN US$98author fair value 03 Mayauthor updated this narrative Labor Shortages Will Hurt Margins Yet Spark Efficiency Gains	PE 52.4x	E 49.6%	US$113.25
4042 Tosoh 8.9%7D 29.4%3M	JP¥3,019.00 2.0% overvalued intrinsic discount	JP¥2.96kauthor fair value 19 Junauthor updated this narrative Analysts are neutral with a Price Target of ¥2,959 based on 7.5% annual revenue growth forecasts.	PE 22.3x	E 14.1%	JP¥2,958.89
BS6 Yangzijiang Shipbuilding (Holdings) 8.3%7D -9.2%3M	S$3.65 33.2% undervalued intrinsic discount	KA S$5.46author fair value 04 Junauthor updated this narrative Yangzijiang Shipbuilding Aims for a 30% Profit Margin Boost	PE 8.8x	E 9.4%	S$4.46
MLYS Mineralys Therapeutics 5.8%7D 7.9%3M	US$25.13 50.6% undervalued intrinsic discount	AN US$50.88author fair value 05 Marauthor updated this narrative Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech	PB 3.2x	E 56.8%	US$49.00
RUSTA Rusta 5.1%7D -17.9%3M	SEK 75.50 22.6% undervalued intrinsic discount	AN SEK 97.5author fair value 03 Junauthor updated this narrative Upcoming Store Expansion And Supply Chain Investments Will Increase Future Market Reach	PE 21x	E 14.7%	SEK 89.33
CS AXA 4.9%7D 10.6%3M	€42.53 8.5% undervalued intrinsic discount	AN €46.48author fair value 03 Junauthor updated this narrative CS: Rising Profit Margins And Multiples Will Drive Global Expansion	PE 12x	E 6.7%	€47.51
ALHC Alignment Healthcare 4.2%7D 18.0%3M	US$21.42 14.1% undervalued intrinsic discount	AN US$24.92author fair value 30 Mayauthor updated this narrative ALHC: Margin Recovery Will Drive Medicare Advantage Market Share Gains	PS 1x	E 39.5%	US$24.92
AGS ageas 4.1%7D 12.3%3M	€67.75 5.7% overvalued intrinsic discount	AN €64.11author fair value 12 Decauthor updated this narrative Asian Life Shift And Esure Integration Will Drive Stronger, More Resilient Earnings Ahead	PE 7.5x	E 0.2%	€67.45
MFC Manulife Financial 4.0%7D 22.3%3M	CA$56.97 2.9% overvalued intrinsic discount	AN CA$55.38author fair value 05 Junauthor updated this narrative MFC: Sector Headwinds And Mixed Performance Will Shape Near-Term Outlook	PE 16.1x	E 10.1%	CA$55.38
BAER Julius Bär Gruppe 3.4%7D 16.5%3M	CHF 65.90 5.0% undervalued intrinsic discount	AN CHF 69.35author fair value 18 Junauthor updated this narrative Digital Transformation And Global Wealth Transfers Will Empower Private Banking	PE 17.7x	E 13.6%	CHF 69.35
MELI MercadoLibre 2.7%7D -2.1%3M	US$1,631.82 28.6% undervalued intrinsic discount	JO US$2.28kauthor fair value 20 Mayauthor updated this narrative MercadoLibre's 19% Revenue Growth Will Propel Their Future Success	PE 43.1x	E 26.7%	US$2,216.96
PNFP Pinnacle Financial Partners 2.7%7D 15.2%3M	US$95.58 18.2% undervalued intrinsic discount	AN US$116.79author fair value 05 Junauthor updated this narrative PNFP: Revenue Momentum And Pending Synovus Merger Will Drive Future Upside	PE 23x	E 51.4%	US$116.53
966 China Taiping Insurance Holdings 2.6%7D -2.1%3M	HK$21.26 15.7% undervalued intrinsic discount	HK$25.23author fair value 19 Junauthor updated this narrative Analysts are bullish with a Price Target of HK$25.23 based on 103.3% annual revenue growth forecasts.	PE 2.9x	E -17.3%	HK$25.23
BDT Bird Construction 2.3%7D 72.0%3M	CA$59.87 5.5% undervalued intrinsic discount	AN CA$63.38author fair value 17 Junauthor updated this narrative Sustained Sector Optimism And Major Project Wins Will Support Long-Term Expansion	PE 67.1x	E 49.2%	CA$63.38
ARGX argenx 2.3%7D 31.5%3M	€780.20 13.7% overvalued intrinsic discount	KA €686.43author fair value 20 Mayauthor updated this narrative High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug	PE 37.4x	E 21.7%	€849.01
4206 Aica Kogyo Company 2.1%7D -3.0%3M	JP¥3,533.00 12.8% undervalued intrinsic discount	JP¥4.05kauthor fair value 25 Julauthor updated this narrative Analysts are bullish with a Price Target of ¥4,050 based on 10.5% annual revenue growth forecasts.	PE 12.1x	E 5.1%	JP¥4,050.00
LKNC.Y Luckin Coffee 1.3%7D -9.7%3M	US$30.69 32.7% undervalued intrinsic discount	AN US$45.58author fair value 05 Junauthor updated this narrative Chinese Urbanization And Digital Transformation Will Unlock Market Potential	PE 18.7x	E 22.0%	US$45.40
8795 T&D Holdings 1.3%7D 27.1%3M	JP¥4,746.00 5.3% overvalued intrinsic discount	AN JP¥4.51kauthor fair value 02 Mayauthor updated this narrative Analysts Lift T&D Holdings Price Target as Revenue Outlook Improves Despite Lower Margins	PE 16.4x	E 6.0%	JP¥4,901.11
ADS adidas 0.6%7D 29.9%3M	€173.10 12.7% undervalued intrinsic discount	AN €198.28author fair value 04 Junauthor updated this narrative ADS: Stable Profit Margins Will Support Renewed Confidence Amid Legal Scrutiny	PE 22.1x	E 14.7%	€199.71
HBAN Huntington Bancshares 0.06%7D 11.1%3M	US$16.85 66.7% overvalued intrinsic discount	MS US$10.11author fair value 27 Sepauthor updated this narrative Overvalued HBAN	PE 16.5x	E 16.2%	US$19.84
999 Xiaocaiyuan International Holding 0%7D -13.5%3M	HK$6.80 25.1% undervalued intrinsic discount	HK$9.08author fair value 19 Decauthor updated this narrative Analysts are bullish with a Price Target of HK$9.08 based on 3.8% annual revenue growth forecasts.	PE 9.6x	E 6.8%	HK$9.08
9911 Newborn Town 0%7D -9.9%3M	HK$8.18 41.4% undervalued intrinsic discount	HK$13.97author fair value 25 Julauthor updated this narrative Analysts are bullish with a Price Target of HK$13.97 based on 24.4% annual revenue growth forecasts.	PE 10.6x	E 16.7%	HK$13.97
FITB Fifth Third Bancorp -0.1%7D 20.4%3M	US$52.58 8.4% undervalued intrinsic discount	AN US$57.42author fair value 06 Junauthor updated this narrative Analyst Commentary Highlights Optimism and Caution on Fifth Third Bancorp Amid Merger and Valuation Shifts	PE 23.5x	E 22.6%	US$57.53
DKSH DKSH Holding -0.2%7D 9.4%3M	CHF 62.60 13.7% undervalued intrinsic discount	AN CHF 72.57author fair value 11 Febauthor updated this narrative Asia Pacific Expansion And Digitalization Will Fuel Sustainable Success	PE 20x	E 9.4%	CHF 73.93
NIC Nicolet Bankshares -0.2%7D 2.2%3M	US$144.55 17.0% undervalued intrinsic discount	US$174.2author fair value 25 Julauthor updated this narrative Analysts are bullish with a Price Target of $174.20 based on 27.0% annual revenue growth forecasts.	PE 23x	E 40.5%	US$174.20
EXEL Exelixis -0.3%7D 27.1%3M	US$52.44 5.6% overvalued intrinsic discount	AN US$49.65author fair value 11 Junauthor updated this narrative Expanding Global Oncology Markets Will Broaden Patient Access	PE 15.8x	E 12.1%	US$49.00
ONC BeOne Medicines -0.4%7D -7.1%3M	US$262.68 36.2% undervalued intrinsic discount	AN US$411.51author fair value 23 Mayauthor updated this narrative ONC: Pivotal Oncology Trial Data Will Drive Future Upside Momentum	PE 56.9x	E 29.0%	US$412.35
939 China Construction Bank -0.5%7D 7.7%3M	HK$8.71 11.1% undervalued intrinsic discount	AN HK$9.8author fair value 17 Junauthor updated this narrative Mounting Headwinds And Digital Shifts Will Suppress Future Margins	PE 5.8x	E 5.4%	HK$10.73
COLB Columbia Banking System -0.9%7D 13.8%3M	US$30.05 6.3% undervalued intrinsic discount	AN US$32.08author fair value 06 Junauthor updated this narrative COLB: Upgraded Ratings And Peer-Leading Returns Will Drive Outperformance	PE 13.3x	E 17.5%	US$32.08
SFNC Simmons First National -1.1%7D 16.1%3M	US$21.71 7.9% undervalued intrinsic discount	AN US$23.57author fair value 17 Junauthor updated this narrative Urbanization And Digital Adoption Will Transform US Banking	PB 0.9x	E 112.8%	US$23.57
COPN Cosmo -1.1%7D -11.8%3M	CHF 69.70 30.3% undervalued intrinsic discount	KA CHF 100author fair value 16 Mayauthor updated this narrative Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates	PS 11.8x	E 42.0%	CHF 128.38
CCB Coastal Financial -1.4%7D -7.6%3M	US$70.34 33.8% undervalued intrinsic discount	US$106.25author fair value 19 Junauthor updated this narrative Analysts are bullish with a Price Target of $106.25 based on 77.0% annual revenue growth forecasts.	PE 21.8x	E 45.5%	US$106.25
CAMX Camurus -1.7%7D 16.4%3M	SEK 533.00 30.8% undervalued intrinsic discount	AN SEK 770.13author fair value 29 Aprauthor updated this narrative Global Expansion And Regulatory Approvals Will Transform Healthcare Delivery	PE 46.5x	E 34.9%	SEK 771.38
RNST Renasant -1.8%7D 18.8%3M	US$41.20 9.6% undervalued intrinsic discount	AN US$45.57author fair value 15 Junauthor updated this narrative Southeastern Expansion And Merger Synergies Will Create Value	PE 16.7x	E 22.6%	US$45.57
MONY MONY Group -2.1%7D 13.2%3M	UK£1.82 35.0% undervalued intrinsic discount	AN UK£2.8author fair value 04 Junauthor updated this narrative Rising Middle Class And AI Integration Will Expand Markets	PE 11.6x	E 7.0%	UK£2.28
RHM Rheinmetall -2.3%7D -24.5%3M	€1,170.20 38.1% undervalued intrinsic discount	AN €1.89kauthor fair value 15 Junauthor updated this narrative Analysts Highlight Cautious Optimism Amid Valuation Gains and Strategic Shifts at Rheinmetall	PE 51.9x	E 30.8%	€1,889.38
MRP Millrose Properties -2.6%7D -3.4%3M	US$28.06 27.3% undervalued intrinsic discount	AN US$38.6author fair value 14 Decauthor updated this narrative Long-Term Housing Undersupply And AI Underwriting Will Support Strong Future Performance	PE 10.1x	E 5.5%	US$37.60
MRK Merck -3.1%7D 1.1%3M	US$115.44 2.6% overvalued intrinsic discount	BU US$112.55author fair value 28 Sepauthor updated this narrative Merck & Co.: Navigating Pharmaceutical Frontiers Amidst Patent Challenges	PE 31.9x	E 21.2%	US$129.74
EVO Evolution -3.3%7D 19.4%3M	SEK 699.40 32.8% undervalued intrinsic discount	IM SEK 1.04kauthor fair value 04 Junauthor updated this narrative A Monopoly-Quality Business Trading at Distress Multiples — CEO Buying, €346M Buyback Active, 73% Upside to Fair Value	PE 12x	E 4.3%	SEK 674.88
HRMY Harmony Biosciences Holdings -4.8%7D 21.4%3M	US$33.77 28.6% undervalued intrinsic discount	AN US$47.3author fair value 23 Febauthor updated this narrative Expanding Sleep And Rare Disease Markets Will Unlock Future Potential	PE 13.4x	E 18.2%	US$44.36
HACK Hacksaw -5.0%7D 26.7%3M	SEK 73.70 26.2% undervalued intrinsic discount	AN SEK 99.87author fair value 25 Janauthor updated this narrative Expanding Games Portfolio And New Regulated Markets Will Support Long Term Earnings Potential	PE 12.6x	E 24.8%	SEK 103.49
BETS B Betsson -5.1%7D -10.4%3M	SEK 87.15 47.8% undervalued intrinsic discount	IM SEK 167author fair value 04 Junauthor updated this narrative The Market Is Paying You a 9.3% Dividend and an 18.9% FCF Yield to Wait for a Recovery That's Already Starting	PE 7x	E 0.7%	SEK 96.67
2419 Dekon Food and Agriculture Group -7.6%7D -40.5%3M	HK$45.96 54.5% undervalued intrinsic discount	HK$101.02author fair value 25 Julauthor updated this narrative Analysts are bullish with a Price Target of HK$101.02 based on 10.0% annual revenue growth forecasts.	PE 10.7x	E 51.4%	HK$101.02
MNSO MINISO Group Holding -7.7%7D -27.6%3M	US$12.15 52.3% undervalued intrinsic discount	BE US$25.46author fair value 14 Junauthor updated this narrative MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x	PE 12.2x	E 19.6%	US$20.37

Beat the Benchmark 2026 Portfolio - Possible list

Watching

Analysts are bullish with a Price Target of A$8.13 based on 65.4% annual revenue growth forecasts.

AU: Strengthening Margins And Revenue Will Drive Upward Momentum In Coming Years

Analysts Lift Alamos Gold Price Target Amid Strong Growth Improved Margins and Positive Outlook

Labor Shortages Will Hurt Margins Yet Spark Efficiency Gains

Analysts are neutral with a Price Target of ¥2,959 based on 7.5% annual revenue growth forecasts.

Yangzijiang Shipbuilding Aims for a 30% Profit Margin Boost

Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech

Upcoming Store Expansion And Supply Chain Investments Will Increase Future Market Reach

CS: Rising Profit Margins And Multiples Will Drive Global Expansion

ALHC: Margin Recovery Will Drive Medicare Advantage Market Share Gains

Asian Life Shift And Esure Integration Will Drive Stronger, More Resilient Earnings Ahead

MFC: Sector Headwinds And Mixed Performance Will Shape Near-Term Outlook

Digital Transformation And Global Wealth Transfers Will Empower Private Banking

MercadoLibre's 19% Revenue Growth Will Propel Their Future Success

PNFP: Revenue Momentum And Pending Synovus Merger Will Drive Future Upside

Analysts are bullish with a Price Target of HK$25.23 based on 103.3% annual revenue growth forecasts.

Sustained Sector Optimism And Major Project Wins Will Support Long-Term Expansion

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Analysts are bullish with a Price Target of ¥4,050 based on 10.5% annual revenue growth forecasts.

Chinese Urbanization And Digital Transformation Will Unlock Market Potential

Analysts Lift T&D Holdings Price Target as Revenue Outlook Improves Despite Lower Margins

ADS: Stable Profit Margins Will Support Renewed Confidence Amid Legal Scrutiny

Overvalued HBAN

Analysts are bullish with a Price Target of HK$9.08 based on 3.8% annual revenue growth forecasts.

Analysts are bullish with a Price Target of HK$13.97 based on 24.4% annual revenue growth forecasts.

Analyst Commentary Highlights Optimism and Caution on Fifth Third Bancorp Amid Merger and Valuation Shifts

Asia Pacific Expansion And Digitalization Will Fuel Sustainable Success

Analysts are bullish with a Price Target of $174.20 based on 27.0% annual revenue growth forecasts.

Expanding Global Oncology Markets Will Broaden Patient Access

ONC: Pivotal Oncology Trial Data Will Drive Future Upside Momentum

Mounting Headwinds And Digital Shifts Will Suppress Future Margins

COLB: Upgraded Ratings And Peer-Leading Returns Will Drive Outperformance

Urbanization And Digital Adoption Will Transform US Banking

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Analysts are bullish with a Price Target of $106.25 based on 77.0% annual revenue growth forecasts.

Global Expansion And Regulatory Approvals Will Transform Healthcare Delivery

Southeastern Expansion And Merger Synergies Will Create Value

Rising Middle Class And AI Integration Will Expand Markets

Analysts Highlight Cautious Optimism Amid Valuation Gains and Strategic Shifts at Rheinmetall

Long-Term Housing Undersupply And AI Underwriting Will Support Strong Future Performance

Merck & Co.: Navigating Pharmaceutical Frontiers Amidst Patent Challenges

A Monopoly-Quality Business Trading at Distress Multiples — CEO Buying, €346M Buyback Active, 73% Upside to Fair Value

Expanding Sleep And Rare Disease Markets Will Unlock Future Potential

Expanding Games Portfolio And New Regulated Markets Will Support Long Term Earnings Potential

The Market Is Paying You a 9.3% Dividend and an 18.9% FCF Yield to Wait for a Recovery That's Already Starting

Analysts are bullish with a Price Target of HK$101.02 based on 10.0% annual revenue growth forecasts.

MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x

Watching

Analysts are bullish with a Price Target of A$8.13 based on 65.4% annual revenue growth forecasts.

AU: Strengthening Margins And Revenue Will Drive Upward Momentum In Coming Years

Analysts Lift Alamos Gold Price Target Amid Strong Growth Improved Margins and Positive Outlook

Labor Shortages Will Hurt Margins Yet Spark Efficiency Gains

Analysts are neutral with a Price Target of ¥2,959 based on 7.5% annual revenue growth forecasts.

Yangzijiang Shipbuilding Aims for a 30% Profit Margin Boost

Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech

Upcoming Store Expansion And Supply Chain Investments Will Increase Future Market Reach

CS: Rising Profit Margins And Multiples Will Drive Global Expansion

ALHC: Margin Recovery Will Drive Medicare Advantage Market Share Gains

Asian Life Shift And Esure Integration Will Drive Stronger, More Resilient Earnings Ahead

MFC: Sector Headwinds And Mixed Performance Will Shape Near-Term Outlook

Digital Transformation And Global Wealth Transfers Will Empower Private Banking

MercadoLibre's 19% Revenue Growth Will Propel Their Future Success

PNFP: Revenue Momentum And Pending Synovus Merger Will Drive Future Upside

Analysts are bullish with a Price Target of HK$25.23 based on 103.3% annual revenue growth forecasts.

Sustained Sector Optimism And Major Project Wins Will Support Long-Term Expansion

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Analysts are bullish with a Price Target of ¥4,050 based on 10.5% annual revenue growth forecasts.

Chinese Urbanization And Digital Transformation Will Unlock Market Potential

Analysts Lift T&D Holdings Price Target as Revenue Outlook Improves Despite Lower Margins

ADS: Stable Profit Margins Will Support Renewed Confidence Amid Legal Scrutiny

Overvalued HBAN

Analysts are bullish with a Price Target of HK$9.08 based on 3.8% annual revenue growth forecasts.

Analysts are bullish with a Price Target of HK$13.97 based on 24.4% annual revenue growth forecasts.

Analyst Commentary Highlights Optimism and Caution on Fifth Third Bancorp Amid Merger and Valuation Shifts

Asia Pacific Expansion And Digitalization Will Fuel Sustainable Success

Analysts are bullish with a Price Target of $174.20 based on 27.0% annual revenue growth forecasts.

Expanding Global Oncology Markets Will Broaden Patient Access

ONC: Pivotal Oncology Trial Data Will Drive Future Upside Momentum